Results 161 to 170 of about 46,872 (214)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Lipid Modulation in Heart Failure: A Narrative Review. [PDF]

Cureus
Neshat S, Moradi H, Bidares M, Heidari A, Falahati Marvast A, Ortega R, Heshmat K.   +6 more
europepmc   +1 more source

Authors' reply to: 'preventing atrial fibrillation with SGLT2 inhibitors: time, sex, and substrate' by Karakasis et al. [PDF]

Eur Heart J Cardiovasc Pharmacother
Fedele D, Amicone S, Canton L, Angeli F, Armillotta M, Bergamaschi L, Pizzi C.   +6 more
europepmc   +1 more source

The Role of SGLT2 Inhibitors in Atherosclerosis: A Systematic Review. [PDF]

J Community Hosp Intern Med Perspect
Maik MHBA, Ibtisam M, Sheikh S, Malik MABA, Ihsan A, Arham M, Haq U, Parveen A.   +7 more
europepmc   +1 more source

Assessing Potential Valve-Preserving Effects of SGLT2 Inhibitors in Degenerative Aortic Stenosis: A Propensity-Matched Study. [PDF]

J Clin Med
Morel O, Guglieri M, Trimaille A, Marchandot B, Bisson A, Granier A, Schini-Kerth V, Bernard A, Fauchier L.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Cardiovascular benefit of SGLT2 inhibitors

Critical Reviews in Clinical Laboratory Sciences, 2021
Patients with type 2 diabetes mellitus (T2D) are at increased risk of cardiovascular (CV) disease. Sodium glucose cotransporter 2 (SGLT2) inhibitors, also known as gliflozins, are a class of medications used to treat T2D by preventing the reabsorption of glucose filtered through the kidney and thereby facilitating glucose excretion in the urine.
Reza, Mohebi, James L, Januzzi
openaire   +2 more sources

SGLT2 inhibitors

Biochemical Pharmacology, 2016
Diabetes mellitus is a serious health issue and an economic burden, rising in epidemic proportions over the last few decades worldwide. Although several treatment options are available, only half of the global diabetic population achieves the recommended or individualized glycemic targets.
I, Dardi, T, Kouvatsos, S A, Jabbour
openaire   +2 more sources

[SGLT2 inhibitors : only beneficial ?]

Revue medicale suisse, 2021
SGLT2 inhibitors are more and more prescribed in the treatment of type 2 diabetes. Their cardioprotective and nephroprotective effects make them particularly attractive. However, it is important to be aware of their potential side effects. This article aims to summarize the actual evidence regarding the most studied ones.
Lucie, Sciotto, Francois R, Jornayvaz
openaire   +2 more sources